Baxter International Inc (NYSE:BAX) Receives Average Recommendation of “Buy” from Brokerages

Shares of Baxter International Inc (NYSE:BAX) have earned a consensus rating of “Buy” from the seventeen ratings firms that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $85.00.

A number of research firms have recently issued reports on BAX. KeyCorp began coverage on Baxter International in a report on Tuesday, June 25th. They issued a “sector weight” rating on the stock. ValuEngine lowered Baxter International from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Royal Bank of Canada set a $87.00 price objective on Baxter International and gave the stock a “hold” rating in a report on Friday, July 26th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Baxter International in a report on Tuesday, September 10th. Finally, Credit Suisse Group upped their price objective on Baxter International from $84.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 26th.

Shares of NYSE:BAX traded up $0.42 during trading on Monday, reaching $88.03. The company had a trading volume of 2,116,085 shares, compared to its average volume of 2,609,292. The firm has a market capitalization of $44.94 billion, a price-to-earnings ratio of 28.86, a price-to-earnings-growth ratio of 2.01 and a beta of 0.99. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10. The stock’s fifty day moving average price is $87.00 and its 200 day moving average price is $81.69. Baxter International has a fifty-two week low of $61.05 and a fifty-two week high of $89.93.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.08. The business had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.80 billion. Baxter International had a return on equity of 21.21% and a net margin of 14.28%. The company’s revenue for the quarter was down .1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.77 earnings per share. On average, equities analysts anticipate that Baxter International will post 3.37 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, October 1st. Investors of record on Friday, August 30th were issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date was Thursday, August 29th. Baxter International’s dividend payout ratio is presently 28.85%.

In other Baxter International news, Director James R. Gavin III sold 7,950 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $87.63, for a total value of $696,658.50. Following the sale, the director now owns 40,932 shares of the company’s stock, valued at $3,586,871.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jacqueline Kunzler sold 5,934 shares of the company’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $88.12, for a total value of $522,904.08. Following the completion of the sale, the senior vice president now directly owns 3,089 shares in the company, valued at approximately $272,202.68. The disclosure for this sale can be found here. Insiders have sold 14,064 shares of company stock worth $1,235,359 in the last ninety days. 0.70% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in Baxter International by 1.4% in the second quarter. BlackRock Inc. now owns 40,589,288 shares of the medical instruments supplier’s stock valued at $3,324,263,000 after purchasing an additional 560,814 shares during the last quarter. Morgan Stanley grew its holdings in Baxter International by 5.5% in the second quarter. Morgan Stanley now owns 17,154,303 shares of the medical instruments supplier’s stock valued at $1,404,937,000 after purchasing an additional 895,279 shares during the last quarter. Northern Trust Corp grew its holdings in Baxter International by 0.6% in the second quarter. Northern Trust Corp now owns 8,758,537 shares of the medical instruments supplier’s stock valued at $717,323,000 after purchasing an additional 54,889 shares during the last quarter. Veritas Asset Management LLP grew its holdings in Baxter International by 0.5% in the second quarter. Veritas Asset Management LLP now owns 7,886,549 shares of the medical instruments supplier’s stock valued at $645,908,000 after purchasing an additional 35,600 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its holdings in Baxter International by 43.4% in the second quarter. Caisse DE Depot ET Placement DU Quebec now owns 6,430,469 shares of the medical instruments supplier’s stock valued at $526,655,000 after purchasing an additional 1,945,800 shares during the last quarter. 83.44% of the stock is currently owned by institutional investors.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Recommended Story: Institutional Investors

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.